Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1979-1985

  Soma, Daisuke ^a   Kitayama, Joji ^a   Konno, Tomohiro ^b   Ishihara, Kazuhiko ^b   Yamada, Jun ^a   Kamei, Takao ^a   Ishigami, Hironori ^a   Kaisaki, Shoichi ^a   Nagawa, Hirokazu ^a  

^a Division of Surgical Oncology   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; CREMOPHOR; PACLITAXEL; POLY(2 METHACRYLOXYETHYL PHOSPHORYLCHOLINE CO N BUTYL METHACRYLATE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; METHACRYLATES; MICE; MICE, NUDE; PACLITAXEL; PERITONEAL NEOPLASMS; PHOSPHORYLCHOLINE; STOMACH NEOPLASMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349592985     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01265.x     Document Type: Article

References (50)

1. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000, 87:236-42.
2. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989, 63:364-7.
3. Brigand C, Arvieux C, Gilly FN, Glehen O. Treatment of peritoneal carcinomatosis in gastric cancers. Dig Dis 2004, 22:366-73.
4. Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs 2008, 13:135-44.
5. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996, 82:53-63.
6. Hagiwara A, Togawa T, Yamasaki J. Extensive gastrectomy and carbon-adsorbed mitomycin C for gastric cancer with peritoneal metastases. Case reports of survivors and their implications. Hepatogastroenterology 1999, 46:1673-7.
7. Hagiwara A, Takahashi T, Sawai K. Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites - a pilot study. Anticancer Drug Des 1993, 8:463-70.
8. Demicheli R, Bonciarelli G, Jirillo A. Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration. Tumori 1985, 71:63-8.
9. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-7.
10. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990, 82:1247-59.
11. Eiseman JL, Eddington ND, Leslie J. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994, 34:465-71.
12. Gelderblom H, Verweij J, van Zomeren DM. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002, 8:1237-41.
13. Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
14. Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-7.
15. de Bree E, Rosing H, Michalakis J. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006, 32:666-70.
16. Kodera Y, Ito Y, Ito S. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 2007, 54:960-3.
17. Tamura S, Miki H, Okada K. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. Int J Clin Oncol 2008, 13:536-40.
18. Weiss RB, Donehower RC, Wiernik PH. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-8.
19. Lorenz W, Reimann HJ, Schmal A. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977, 7:63-7.
20. Auzenne E, Donato NJ, Li C. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002, 8:573-81.
21. Sharma A, Mayhew E, Bolcsak L. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 1997, 71:103-7.
22. Merisko-Liversidge E, Sarpotdar P, Bruno J. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996, 13:272-8.
23. Gradishar WJ, Tjulandin S, Davidson N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-803.
24. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006, 100:437-8. 3rd
25. Hamaguchi T, Matsumura Y, Suzuki M. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-6.
26. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-92.
27. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-84.
28. Kimura M, Konno T, Oda T, Maeda H, Miyauchi Y. Intracavitary treatment of malignant ascitic carcinomatosis with oily anticancer agents in rats. Anticancer Res 1993, 13:1287-92.
29. Kimura M, Konno T, Miyamoto Y, Kojima Y, Maeda H. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res 1998, 18:2547-50.
30. Ishihara K, Ziats NP, Tierney BP, Nakabayashi N, Anderson JM. Protein adsorption from human plasma is reduced on phospholipid polymers. J Biomed Mater Res 1991, 25:1397-407.
31. Ishihara K, Iwasaki Y, Nakabayashi N. Polymeric lipid nanosphere consisting of water-soluble poly (2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate). Polym J 1999, 31:1231-6.
32. Konno T, Watanabe J, Ishihara K. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 2003, 65:209-14.
33. Wada M, Jinno H, Ueda M. Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel. Anticancer Res 2007, 27:1431-5.
34. Ishihara K, Ueda T, Nakabayashi N. Preparation of phospholipid polymers and their properties as polymer hydrogel membrane. Polym J 1990, 22:355-60.
35. Sako A, Kitayama J, Koyama H. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res 2004, 64:3624-8.
36. Lee SH, Yoo SD, Lee KH. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999, 724:357-63.
37. Shih WJ, Coupal JJ, Chia HL. Communication between peritoneal cavity and mediastinal lymph nodes demonstrated by Tc-99m albumin nanocolloid intraperitoneal injection. Proc Natl Sci Counc Repub China B 1993, 17:103-5.
38. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am 2003, 12:813-24.
39. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A 2006, 77:351-61.
40. Lu H, Li B, Kang Y. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol 2007, 59:175-81.
41. Lankelma J, Dekker H, Luque FR. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999, 5:1703-7.
42. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005, 11(24 Pt 1):8782-8.
43. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-92.
44. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as 'soil' for peritoneal dissemination. Cancer 1996, 77(8 Suppl):1668-75.
45. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994, 271:58-65.
46. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol 2002, 84:36-42.
47. Bristow RE, Zahurak ML, del Carmen MG. Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 2004, 93:353-60.
48. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003, 42:665-85.
49. Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999, 44:241-8.
50. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 2005, 16:122-30.